Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21910237 | 0.90 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831226 | 0.90 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831225 | 0.90 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL3919530 | 0.84 | MEN1 (0.50) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL21831877 | 0.81 | SIGMAR1 (0.39) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831186 | 0.81 | SIGMAR1 (0.39) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831184 | 0.81 | SIGMAR1 (0.39) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL30910922 | 0.80 | SIGMAR1 (0.38) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831083 | 0.78 | SIGMAR1 (0.40) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL21831856 | 0.77 | SIGMAR1 (0.39) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546103-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMA (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20040180880-A1 | Piperazine and piperidine derivatives | LAUFFER DAVID J (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180880-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | OPRM1 2677/4885OPRD1 1717/4885OPRK1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.